|
 Academic Year: | 2016/7 |
| Owning Department/School: | Department of Pharmacy & Pharmacology |
| Credits: | 6 [equivalent to 12 CATS credits] |
| Notional Study Hours: | 120 |
| Level: | Masters UG & PG (FHEQ level 7) |
| Period: |
|
| Assessment Summary: | EX 100% |
| Assessment Detail: |
|
| Supplementary Assessment: |
|
| Requisites: | |
| Description:
| Aims: To familiarise the student with recent advances in molecular and cellular processes underlying tumour development and its treatment. Learning Outcomes: On successful completion of this unit, the student should be able to demonstrate an in-depth knowledge and understanding of the disease process in cancer and the complexity of its treatment, to evaluate critically this knowledge in order to resolve conflicting issues and thus identify and analyse rational treatment protocols. Skills: Scientific skills (T/F/A) Study skills, handling information, working with others (T/F) Problem solving (T/F) Content: Epidemiological studies of cancer and a recognition of how this approach retains validity. Chemical mutagenesis. Cell biology of tumour development including apoptosis, oncogenes and tumour suppressor genes. The molecular mechanisms of action of the major classes of drugs currently in use and their shortcomings. Active and passive immunotherapy. Then either the clinical or research setting; palliative or curative treatment, relationship to surgery, chemotherapy or radiotherapy, risk-benefit analysis. CRM Guidelines on safe handling of cytotoxic agents. |
| Programme availability: |
PA40157 is a Designated Essential Unit on the following programmes:Department of Pharmacy & Pharmacology
PA40157 is Optional on the following programmes:Department of Pharmacy & Pharmacology
|
Notes:
|